Literature DB >> 20139198

Extracorporeal membrane oxygenation for intraoperative cardiac support in children with congenital heart disease.

Eva Maria Delmo Walter1, Vladimir Alexi-Meskishvili, Michael Huebler, Antonino Loforte, Brigitte Stiller, Yuguo Weng, Wolfgang Boettcher, Felix Berger, Roland Hetzer.   

Abstract

OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) is commonly used in children to allow recovery from ischemic injury or cardiac surgery, to support the circulation in case of end-stage cardiomyopathy, as bridge-to-bridge therapy and as bridge to transplantation as well. It has achieved success in providing cardiac support for these kind of patients with expected mortality due to severe myocardial dysfunction. In this modern era, ECMO support should be considered an important option for children with cardiopulmonary failure refractory to medical therapy or resuscitation. We report our experience in pediatric patients supported by ECMO for intraoperative cardiac failure between November 1991 and December 2006. METHODS AND
RESULTS: Sixty-six patients with a mean age of 5.2+/-4 years (range: 1 day-17 years) and mean weight of 14.3+/-11 kg (range: 2.8-69 kg) had intraoperative ECMO support for failure to wean off cardiopulmonary bypass (n=46, 69.7%), low cardiac output syndrome (n=8, 12.1%), isolated right ventricular failure (n=6, 9.1%), isolated left ventricular failure (n=3, 4.5%), malignant arrhythmia (n=1, 1.5%) and pulmonary hypertension (n=2, 3.1%). Mean duration of ECMO support was 5.1+/-3 days. Overall 30 (45.4%) patients were successfully weaned off ECMO and survived to decannulation. Overall 6 (9.1%) patients were successfully bridged to heart transplantation while on ECMO support. Thirty patients died (54.4%) (16 while on ECMO and 14 after decannulation) because of multi-factorial complications, i.e. cerebral hemorrhage, pulmonary failure, consumption coagulopathy and therapy-resistant myocardial insufficiency, leding to an overall hospital mortality rate of 45.4%. Mean survival time after decannulation was 28+/-16 h. Overall survival rate on ECMO as bridge to recovery and transplantation has been 54.5% with successful hospital discharge of patients.
CONCLUSIONS: Our experience shows that ECMO support can be offered intraoperatively to any children after palliative or corrective surgery for congenital heart disease with potentially reversible pulmonary, cardiac or cardiopulmonary failure. In the majority of patients who did not survive late after weaning from ECMO support, significant myocardial dysfunction persisted or pulmonary hypertensive events. Nevertheless, an acceptable proportion of patients who were successfully weaned from ECMO ultimately survived to leave the hospital. 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20139198     DOI: 10.1510/icvts.2009.220475

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  13 in total

Review 1.  Extra-corporeal membrane oxygenation for the post-cardiotomy patient.

Authors:  Priyadharshanan Ariyaratnam; Lindsay A McLean; Alexander R J Cale; Mahmoud Loubani
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

2.  The national heart, lung, and blood institute pediatric circulatory support program: a summary of the 5-year experience.

Authors:  J Timothy Baldwin; Harvey S Borovetz; Brian W Duncan; Mark J Gartner; Robert K Jarvik; William J Weiss
Journal:  Circulation       Date:  2011-03-22       Impact factor: 29.690

3.  Modern Outcomes of Mechanical Circulatory Support as a Bridge to Pediatric Heart Transplantation.

Authors:  Brody Wehman; Kristen A Stafford; Gregory J Bittle; Zachary N Kon; Charles F Evans; Keshava Rajagopal; Nicholas Pietris; Sunjay Kaushal; Bartley P Griffith
Journal:  Ann Thorac Surg       Date:  2016-02-22       Impact factor: 4.330

4.  Institution of Veno-arterial Extracorporeal Membrane Oxygenation Does Not Lead to Increased Wall Stress in Patients with Impaired Myocardial Function.

Authors:  Andrew M Koth; David M Axelrod; Sushma Reddy; Stephen J Roth; Theresa A Tacy; Rajesh Punn
Journal:  Pediatr Cardiol       Date:  2016-12-22       Impact factor: 1.655

5.  Predictors of mortality in pediatric patients on venoarterial extracorporeal membrane oxygenation.

Authors:  Rajesh Punn; David M Axelrod; Sara Sherman-Levine; Stephen J Roth; Theresa A Tacy
Journal:  Pediatr Crit Care Med       Date:  2014-11       Impact factor: 3.624

6.  Extracorporeal membrane oxygenation in adult patients with congenital heart disease.

Authors:  R J Uilkema; L C Otterspoor
Journal:  Neth Heart J       Date:  2014-11       Impact factor: 2.380

7.  Early clinical outcomes of new pediatric extracorporeal life support system (Endumo (2000) in neonates and infants.

Authors:  Takaya Hoashi; Koji Kagisaki; Kizuku Yamashita; Eisuke Tatsumi; Takayuki Nishigaki; Kotaro Yoshida; Teruyuki Hayashi; Hajime Ichikawa
Journal:  J Artif Organs       Date:  2013-05-30       Impact factor: 1.731

8.  Perioperative mechanical circulatory support in children: an analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database.

Authors:  Christopher E Mascio; Erle H Austin; Jeffrey P Jacobs; Marshall L Jacobs; Amelia S Wallace; Xia He; Sara K Pasquali
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-16       Impact factor: 5.209

9.  Extracorporeal Membrane Oxygenation in a 1,360-g Premature Neonate after Repairing Total Anomalous Pulmonary Venous Return.

Authors:  Youn Ju Rhee; Sung Joon Han; Yoo Young Chong; Min-Woong Kang; Shin Kwang Kang; Jae-Hyeon Yu
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2016-10-05

10.  Use of Therapeutic Plasma Exchange during Extracorporeal Life Support in Critically Ill Cardiac Children with Thrombocytopenia-Associated Multi-Organ Failure.

Authors:  Mei Chong; Alejandro J Lopez-Magallon; Lucas Saenz; Mahesh S Sharma; Andrew D Althouse; Victor O Morell; Ricardo Munoz
Journal:  Front Pediatr       Date:  2017-12-01       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.